HomeCompareCHRRF vs ABBV

CHRRF vs ABBV: Dividend Comparison 2026

CHRRF yields 1.20% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $82.5K in total portfolio value
10 years
CHRRF
CHRRF
● Live price
1.20%
Share price
$16.29
Annual div
$0.20
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$19.9K
Annual income
$0.12
Full CHRRF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — CHRRF vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCHRRFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CHRRF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CHRRF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CHRRF
Annual income on $10K today (after 15% tax)
$102.27/yr
After 10yr DRIP, annual income (after tax)
$0.10/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $21,055.90/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CHRRF + ABBV for your $10,000?

CHRRF: 50%ABBV: 50%
100% ABBV50/50100% CHRRF
Portfolio after 10yr
$61.1K
Annual income
$12,385.94/yr
Blended yield
20.27%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

CHRRF
Analyst Ratings
2
Buy
1
Hold
Consensus: Buy
Altman Z
1.0
Piotroski
7/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CHRRF buys
0
ABBV buys
0
No recent congressional trades found for CHRRF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCHRRFABBV
Forward yield1.20%3.06%
Annual dividend / share$0.20$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%40.6%
Portfolio after 10y$19.9K$102.3K
Annual income after 10y$0.12$24,771.77
Total dividends collected$121.00$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: CHRRF vs ABBV ($10,000, DRIP)

YearCHRRF PortfolioCHRRF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$10,760$60.16$11,550$430.00$790.00ABBV
2$11,544$30.25$13,472$627.96$1.9KABBV
3$12,367$15.16$15,906$926.08$3.5KABBV
4$13,240$7.59$19,071$1,382.55$5.8KABBV
5$14,171$3.80$23,302$2,095.81$9.1KABBV
6$15,165$1.90$29,150$3,237.93$14.0KABBV
7$16,227$0.95$37,536$5,121.41$21.3KABBV
8$17,363$0.47$50,079$8,338.38$32.7KABBV
9$18,579$0.24$69,753$14,065.80$51.2KABBV
10$19,880$0.12$102,337$24,771.77$82.5KABBV

CHRRF vs ABBV: Complete Analysis 2026

CHRRFStock

Chorus Aviation Inc., through its subsidiaries, provides various aviation support services in the United States and Canada. The company operates through two segments, Regional Aviation Services and Regional Aircraft Leasing. The Regional Aviation Services segment includes all three sectors of the regional aviation, such as contract flying, including ACMI and charter operations; aircraft leasing; and maintenance, repair, and overhaul, as well as part sales and technical services. The Regional Aircraft Leasing segment provides aircraft leasing to third-party air operators. As of December 31, 2021, this segment's portfolio of leased aircraft consisted of 62 aircraft of which 56 aircraft were on lease to airline customers, such as 23 Dash 8-400s, 18 ATR72-600s, four CRJ1000s, four E190s, two E195s and five A220-300s. The company was formerly known as Jazz Air Income Fund and changed its name to Chorus Aviation Inc. in January 2011. Chorus Aviation Inc. was incorporated in 2010 and is based in Dartmouth, Canada.

Full CHRRF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this CHRRF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CHRRF vs SCHDCHRRF vs JEPICHRRF vs OCHRRF vs KOCHRRF vs MAINCHRRF vs JNJCHRRF vs MRKCHRRF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.